Dermata Therapeutics, Inc.
For the period ended Sep 30, 2025. Filed Nov 14, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 14, 2025
DRMA$0.76+0.3%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Balance Sheets
| September 30, 2025 | December 31, 2024 | |
|---|---|---|
| (unaudited) | ||
| Assets: | ||
| Cash and cash equivalents | $4,664,127 | $3,161,570 |
| Prepaid expenses and other current assets | 407,283 | 372,318 |
| Total assets | $5,071,410 | $3,533,888 |
| Liabilities and Stockholders’ Equity: | ||
| Liabilities: | ||
| Accounts payable (including related party amounts of $185,300 and $0, respectively) | $453,427 | $808,011 |
| Accrued and other current liabilities (including related party amounts of $28,600 and $0, respectively) | 657,881 | 1,164,783 |
| Total liabilities | 1,111,308 | 1,972,794 |
| Commitments and Contingencies (see Note 6) | - | - |
| Stockholders’ Equity: | ||
| Preferred Stock, par value $0.0001 per share, 10,000,000 shares authorized; no shares issued or outstanding as of September 30, 2025 and December 31, 2024 | - | - |
| Common Stock, par value $0.0001 per share, 250,000,000 shares authorized; 844,457 shares issued and outstanding as of September 30, 2025; 251,725 shares issued and outstanding as of December 31, 2024 | 84 | 25 |
| Additional paid-in capital | 75,332,026 | 67,236,408 |
| Accumulated deficit | (71,372,008) | (65,675,339) |
| Total stockholders’ equity | 3,960,102 | 1,561,094 |
| Total liabilities and stockholders’ equity | $5,071,410 | $3,533,888 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.